The AlphaLISA™ SureFire^® Ultra™ p-STAT5 (Tyr694/699) assay is a sandwich immunoassay for quantitative detection of phospho-STAT5 (phosphorylated on Tyr694/699) in cellular lysates using Alpha Technology.

In the AlphaLISA™ SureFire^® Ultra™ assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure™ agent that immobilizes the other antibody, labeled with a CaptSure™ tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.

AlphaLISA™ SureFire^® Ultra™ kits are compatible with:

• Cell and tissue lysates
• Antibody modulators
• Biotherapeutic antibodies

Alpha SureFire^® kits can be used for:

• Cellular kinase assays
• Receptor activation studies
• Screening

Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.